export const newsData = [
  {
    title: "Congratulations to Mrs. Kimaya Meher on successfully defending her PhD thesis",
    date: "March 1, 2023",
    excerpt:
      "Our lab has been awarded a significant grant to further our research on nanomedicine approaches to neurodegenerative diseases. This funding will support our work on developing targeted nanoparticles that can cross the blood-brain barrier.",
    content:
      'The National Institutes of Health (NIH) has awarded Dr. Jane Lopus and her team a $2.5 million grant to advance their research on nanomedicine approaches to treating neurodegenerative diseases. The five-year grant will support the development of novel nanoparticle delivery systems capable of crossing the blood-brain barrier to deliver therapeutic agents to the central nervous system.\n\n"This grant will allow us to build on our preliminary findings and develop more effective strategies for treating conditions like Alzheimer\'s and Parkinson\'s disease," said Dr. Lopus. "We\'re particularly excited about the potential to deliver therapeutic proteins and nucleic acids to specific regions of the brain."\n\nThe project will involve collaboration with neurologists and biomedical engineers to ensure that the developed technologies address clinical needs and can be translated to patient care.',
    imageSrc: "/placeholder.svg?height=400&width=600",
  },
  {
    title: "New paper published in Science",
    date: "February 15, 2023",
    excerpt:
      "Our groundbreaking research on targeted drug delivery systems has been published in Science. This work represents a significant advance in the field of nanomedicine.",
    content:
      'The Lopus Lab is proud to announce the publication of our latest research in Science. The paper, titled "Programmable nanoparticles for precision drug delivery to cancer cells," describes a novel approach to targeting cancer cells while sparing healthy tissues.\n\nThe research team, led by Dr. Jane Lopus and including postdoctoral researcher Dr. Emily Patel and PhD student Sarah Johnson, developed nanoparticles that can be programmed to recognize specific molecular signatures on cancer cells. Once bound to these cells, the nanoparticles release their therapeutic payload, resulting in highly targeted drug delivery.\n\n"This approach has the potential to revolutionize cancer treatment by dramatically reducing side effects while improving efficacy," said Dr. Lopus. "We\'re now working on translating these findings to clinical applications."\n\nThe paper has already received significant attention from the scientific community and has been highlighted in several news outlets.',
    imageSrc: "/placeholder.svg?height=400&width=600",
  }

]

